Publication Name	World Journal of Clinical Oncology
Manuscript ID	108955
Country	Brazil

Received	2025-04-27 05:38
Peer-Review Started	2025-04-27 05:38
To Make the First Decision
Return for Revision	2025-05-17 07:38
Revised	2025-05-23 13:54
Second Decision	2025-08-11 02:51
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-08-12 09:12
Articles in Press	2025-08-12 09:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-09-11 01:05
Publish the Manuscript Online	2025-09-23 06:48

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten?
Manuscript Source	Invited Manuscript
All Author List	Pedro Luiz Serrano Uson Junior, Kunal C Kadakia and Raphael L C Araujo
ORCID	Author(s) ORCID Number Pedro Luiz Serrano Uson Junior http://orcid.org/0000-0001-6122-1374 Raphael L C Araujo http://orcid.org/0000-0002-7834-5944
Funding Agency and Grant Number
Corresponding Author	Raphael L C Araujo, Adjunct Professor, FACS, MD, PhD, Department of Surgery, Universidade Federal de São Paulo, R. Napoleão de Barros, 715, São Paulo 04024-002, São Paulo, Brazil. raphael.l.c.araujo@gmail.com
Key Words	Pancreas cancer; Neoadjuvant treatment; Chemotherapy; Radiation Therapy; Surgery; Pancreatectomy
Core Tip	Upfront surgery remains essential for patients with truly resectable tumors since surgery followed by adjuvant therapy is evidence-based and should not be abandoned. Moreover, current neoadjuvant treatment for resectable lesions with FOLFIRINOX is insufficient due to poor survival outcomes. Better systemic approaches are needed, and germline testing and precision medicine hold promise but are actionable in only a minority of cases, molecular subtyping should be incorporated into future trial designs.
Publish Date	2025-09-23 06:48
Citation	<p>Uson Junior PLS, Kadakia KC, Araujo RLC. Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten? <i>World J Clin Oncol</i> 2025; 16(9): 108955</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i9/108955.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i9.108955

Full Article (PDF)	WJCO-16-108955-with-cover.pdf
Manuscript File	108955_Auto_Edited_011942.docx
Answering Reviewers	108955-answering-reviewers.pdf
Audio Core Tip	108955-audio.m4a
Conflict-of-Interest Disclosure Form	108955-conflict-of-interest-statement.pdf
Copyright License Agreement	108955-copyright-assignment.pdf
Supplementary Material	108955-supplementary-material.pdf
Peer-review Report	108955-peer-reviews.pdf
Scientific Misconduct Check	108955-scientific-misconduct-check.png
Scientific Editor Work List	108955-scientific-editor-work-list.pdf
CrossCheck Report	108955-crosscheck-report.pdf